The 3-month PDUFA delay removes a near-term catalyst and introduces execution risk. Monitor for any further FDA requests or competitor developments. The stock may trade lower on the delay, but the lack of approvability concerns limits downside. Watch for updates on the August 24, 2026 PDUFA date.
Price Chart
Executive Summary
Biogen and Eisai announced a 3-month FDA review extension for the sBLA of LEQEMBI IQLIK (once-weekly subcutaneous injection) as a starting dose for early Alzheimer's disease, pushing the PDUFA date to August 24, 2026. The FDA requested additional information, classifying it as a major amendment, but has not raised approvability concerns. This delay introduces uncertainty around the launch timeline for the subcutaneous formulation, which is key to expanding patient access and convenience.
Key Facts
- FDA extended review period by 3 months for LEQEMBI IQLIK subcutaneous starting dose sBLA
- New PDUFA action date is August 24, 2026 (previously May 2026)
- FDA classified the additional information request as a major amendment
- FDA has not raised any concerns regarding approvability to date
- Subcutaneous maintenance dosing was already approved on August 26, 2025
- LEQEMBI is approved in over 50 countries worldwide
Financial Impact
Delay of up to 3 months in potential approval of subcutaneous starting dose, which could affect adoption ramp and revenue trajectory for LEQEMBI IQLIK. No specific financial figures provided.
Risk Factors
- Further FDA requests could extend review beyond August 2026
- Competing Alzheimer's treatments may gain market share during delay
- Adoption of subcutaneous formulation may be slower if approval is further delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290827 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access